Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| NASDAQ | USD | Real-time | ||
| BATS Europe | SEK | Delayed | ||
| BATS Europe | GBP | Delayed | ||
| OTC Markets | USD | Delayed | ||
| Derived | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
By Alistair Smout and Pushkala Aripaka LONDON (Reuters) -AstraZeneca is exploring options for the future of its COVID-19 vaccine and expects greater clarity on the matter by the...
By Pushkala Aripaka and Alistair Smout (Reuters) -Second-quarter sales of AstraZeneca (NASDAQ:AZN)'s COVID-19 vaccine more than tripled to $894 million from the first quarter, but...
By Allison Martell, Carl O'Donnell and Cassandra Garrison (Reuters) -Canada and Mexico imported millions of doses of AstraZeneca (NASDAQ:AZN)'s COVID-19 vaccine and offered them...
A better than forecast, but still 2nd highest ever, UK borrowing figure for April failed to move the needle for the FTSE on Tuesday. The UK index was unchanged after the bell, flat...
Here is a list of companies that were popular on the site in the latest week.Argo BlockchainUK listed cryptocurrency miner Argo Blockchain (LON:ARB) was popular after the company...
Reports Q1 results on Tuesday, May 4, before the market openRevenue Expectation: $13.67 billionEPS Expectation: $0.78Despite developing the first authorized COVID-19 vaccine to...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Sell | Buy | Strong Buy |
| Technical Indicators | Strong Sell | Strong Sell | Buy | Strong Sell | Strong Buy |
| Summary | Strong Sell | Strong Sell | Neutral | Neutral | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,632.00 | 2,682.00 | 2,632.00 | -14.0 | -0.53% | 65.05K | London | |||
| 171.90 | 178.55 | 167.40 | -12.05 | -6.55% | 52.63M | London | |||
| 3,170.00 | 3,180.00 | 3,116.00 | +48.0 | +1.54% | 1.14M | London | |||
| 79.25 | 79.25 | 79.25 | 0.00 | 0.00% | 0.00 | London | |||
| 894.40 | 902.60 | 892.80 | -2.20 | -0.24% | 2.15M | London | |||
| 18.00 | 17.70 | 17.70 | +0.750 | +4.35% | 645.21K | London | |||
| 233.25 | 234.55 | 231.60 | +0.10 | +0.04% | 16.12M | London | |||
| 572.20 | 572.60 | 563.60 | +2.80 | +0.49% | 2.57M | London | |||
| 284.10 | 284.40 | 279.30 | +2.50 | +0.89% | 3.76M | London | |||
| 5,075.00 | 5,170.00 | 5,070.00 | -40.0 | -0.78% | 66.13K | London | |||
| 0.0725 | 0.00 | 0.00 | -0.0040 | -5.23% | 46.15M | London | |||
| 572.80 | 586.80 | 562.00 | +12.20 | +2.18% | 9.52M | London | |||
| 343.40 | 351.60 | 323.60 | +4.80 | +1.42% | 1.71M | London | |||
| 329.45 | 333.10 | 327.80 | +2.50 | +0.77% | 40.24M | London | |||
| 36.30 | 36.30 | 36.30 | +1.00 | +2.74% | 412.56K | London |
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company’s marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
